Non-communicable diseases (NCDs) pose a significant global health and economic challenge. As we approach the 4th UN High-Level Meeting (HLM) on NCDs and Mental Health, the pharmaceutical industry outlines its NCD priorities to address this crisis effectively.

Context and Background

Since 2000, NCD-related deaths have risen dramatically, accounting for 74% of global deaths by 2019. Alarmingly, 18 million of the 43 million NCD deaths in 2021 occurred before the age of 70, affecting individuals across all income levels. Despite numerous global commitments, progress on NCD targets remains sluggish. The pharmaceutical industry, through the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), is committed to playing a crucial role in addressing this challenge.

Key Analysis and Insights

In the past decade, 1,408 medicines for NCDs have been launched, with over 9,600 in development. Vaccines, such as those for human papillomavirus (HPV) and Hepatitis B, could prevent over one million cancer cases annually. Yet, many NCDs remain untreatable. Fostering a robust innovation ecosystem and improving awareness and uptake of medical advancements are essential.

NCDs cost the global economy USD 2 trillion each year, projected to reach USD 47 trillion by 2030. Investment in NCD prevention and control yields significant returns. For instance, USD 1 invested in mental health interventions in low- and middle-income countries (LMICs) generates USD 24 in benefits. A 1% increase in GDP allocated to public healthcare in LMICs, with 40% directed to primary NCD care, could save 5 million lives annually. Sustainable financing mechanisms are vital to bridge the funding gap.

Fragmented health systems often hinder effective NCD management. In LMICs, only 10% of hypertension cases are under control, despite affordable treatments. A comprehensive approach that addresses regulatory processes, procurement, and supply chains is necessary.

Accountability across governments, health stakeholders, and industries is crucial for tracking progress on NCD targets. Strengthened national surveillance, biennial reporting to the World Health Assembly, and harmonized accountability frameworks for the pharmaceutical sector can foster collective action. High standards of integrity and anti-corruption measures must underpin these efforts to ensure resources reach those in need.

Implications and Recommendations

The implications of inaction on NCDs are severe, pushing 100 million people into extreme poverty each year due to out-of-pocket healthcare costs. For decision-makers, integrating NCD prevention and care into universal health coverage and primary health systems is essential. Prioritising early screening and vaccination programs, developing actionable financing plans, and strengthening multi-stakeholder partnerships are critical steps forward.

Conclusion

The 4th UN HLM on NCDs and Mental Health presents an opportunity to reaffirm global commitments. The pharmaceutical industry, through IFPMA, is dedicated to advancing innovation, mobilising investment, driving implementation, and ensuring accountability. By aligning policy, financing, and collaborative efforts, we can significantly reduce the NCD burden and move closer to achieving Sustainable Development Goal 3.4 by 2030.

For further insights, visit globalhealthprogress.org. Engage in dialogues shaping the future of NCD prevention and care.

Sources